The Colorado Prescription Drug Affordability Board has deemed Novartis’ blockbuster arthritis drug, Cosentyx, as unaffordable for patients due to its high cost. The board is considering imposing a limit on what Colorado health plans pay for the injectable treatment, which averages around $47,000 per patient. Insurance carriers have reported that Cosentyx contributes to increased premiums, despite it being used by a small percentage of residents compared to other available alternatives. The board’s decision will be further discussed in a follow-up meeting to determine if an upper payment limit will be set for the drug.
Source link
Novartis arthritis drug is unaffordable, Colorado state board decides
